New immunotherapy combo takes on advanced colorectal cancer
NCT ID NCT06934538
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests a new immunotherapy called STC-1010 combined with standard chemotherapy and immune boosters in people with advanced colorectal cancer that cannot be removed by surgery. The study has two parts: first, finding the safest dose in about 21-33 participants, then testing how well it works in about 57-60 more. The goal is to see if the treatment can control the cancer and improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
STC-1010 (an immunotherapy) plus immunostimulants (cyclophosphamide and GM-CSF) and standard chemotherapy (mFOLFOX6 with or without bevacizumab)
What this could lead to
If successful, this could lead to a new treatment option that helps control advanced colorectal cancer and may extend the time without the disease worsening.
What could go wrong
This is an early phase I/IIA trial with a small number of participants, so the treatment may not prove effective or safe in larger studies. Side effects from the immunotherapy and chemotherapy are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE/METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Centre Georges François Leclerc (CGFL)
RECRUITINGDijon, France
Contact Email: •••••@•••••
-
Centre Hospitalier Universitaire de Poitiers (CHU)
NOT_YET_RECRUITINGPoitiers, France
Contact Email: •••••@•••••
-
Centre Léon Bérard (CLB)
NOT_YET_RECRUITINGLyon, France
Contact Email: •••••@•••••
-
Hospices Civils de Lyon (HCL)
RECRUITINGLyon, France
Contact Email: •••••@•••••
-
Institut Bergonié
RECRUITINGBordeaux, France
Contact Email: •••••@•••••
-
Institut Gustave Roussy (IGR)
RECRUITINGVillejuif, France
Contact Email: •••••@•••••
-
Institut Jules Bordet
NOT_YET_RECRUITINGBrussels, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut du Cancer de Montpellier (ICM)
RECRUITINGMontpellier, France
Contact Email: •••••@•••••
-
Johns Hopkins
NOT_YET_RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••